STK11 and lung carcinoma: Previous studies have identified several potential therapeutic vulnerabilities, such as HSP90, in LKB1 mutant lung cancer using cancer cell line models, while the complex immune microenvironment remained to be determined due to the use of cancer cell alone culture28,32,64–66.